140 results about "Liver function" patented technology

A microfluidic 3D-printed hydrogel based on fish liver decellularized extracellular matrix for liver regeneration and a preparation method. The hydrogel is prepared by means of combining fish liver decellularized extracellular matrix (dECM) and gelatin methacryloyl (GelMA), and loading induced pluripotent stem cell-derived hepatocytes (iPSC-heps) for liver regeneration. The microfluidic 3D-printed hydrogel based on fish liver decellularized extracellular matrix exhibits excellent biocompatibility, retains intact endogenous growth factors, maintains the biological activity of cells, ensures the effective encapsulation of the cells, and facilitates the robust functional expression of the iPSC-heps. After in-vivo transplantation, the survival rate and liver function of mice with acute liver failure are significantly improved, and liver regeneration and repair are promoted.

The application discloses an animal bifidobacterium producing bile salt hydrolase and application thereof in neonatal jaundice, and belongs to the technical field of microorganisms. The animal bifidobacterium lactis WXM screened by the application has the effect of relieving neonatal jaundice, can significantly improve weight loss of a jaundice individual in an early life stage, improve abnormal increase of a bilirubin level in serum, improve liver damage, improve the level of an enzyme related to liver function, the expression level of a related inflammatory factor in the liver and the expression level of an enzyme UGT1A1 related to bilirubin metabolism, and has the effect of relieving neonatal jaundice. The strain of the application has high safety and has wide application value in the fields of food, functional food, health products, medicine and the like.

The invention discloses a pharmaceutical composition for improving liver dysfunction, the pharmaceutical composition comprises a tablet core and a coating film, the tablet core comprises 30-40 parts of mono-ammonium glycyrrhizinate (20-30 parts by weight of glycyrrhizin), 20-30 parts of glycine, 20-30 parts of methionine, 55-65 parts of a filler, 2-10 parts of a disintegrating agent, 1-10 parts of an adhesive and 1-10 parts of a lubricant, and the coating film is a gastric soluble film coating; wherein the filling agent is formed by compounding lactose, microcrystalline cellulose, calcium carbonate, calcium hydrophosphate and mannitol, the mass ratio of the lactose to the microcrystalline cellulose to the calcium carbonate to the calcium hydrophosphate to the mannitol is (1-24): (1-35): (1-25): (1-9): (1-9), and the pharmaceutical composition for improving liver dysfunction has good dissolution and stability.

The invention discloses application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period, belongs to the technical field of feed additives, and particularly relates to application of paeonol in preparation of a product for improving liver functions and ovarian functions of laying hens in the later egg laying period. It is found that paeonol can significantly reduce the activity of glutamic-pyruvic transaminase in the liver, significantly reduce the content of cholesterol and the content of triglyceride in serum, significantly reduce hepatic cell fatty degeneration and lipid droplet aggregation in a hepatic tissue pathological section, relieve liver injury and lipid metabolism disorder, and significantly improve the liver function. The paeonol can effectively improve the fatty liver hemorrhagic syndrome of the laying hens in the later egg laying period, and the paeonol can recover the storage capacity of ovary by improving the survival rate of follicles, improve the egg laying performance of the laying hens and improve the egg laying rate.

The invention relates to a lycium barbarum fermented product with a liver protection function as well as a preparation method and application thereof, and belongs to the technical field of fermentation. The fermentation liquor is prepared by taking a specific traditional Chinese medicine compound consisting of radix puerariae, semen hoveniae, fructus lycii, rhizoma polygonati, flos chrysanthemi, pericarpium citri reticulatae and cordyceps militaris as a matrix through a double-bacterium synergistic fermentation process. The preparation method comprises the following steps: firstly, pre-fermenting a compound extract by using Akkermansia muciniphila bacteria, enriching propionic acid and optimizing the matrix; the preparation method comprises the following steps: carrying out primary fermentation by using lactic acid bacteria combined with Lactobacillus paracasei E10, L. paracasei JN-1 and L. paracasei JN-8 (in a volume ratio of 3: 3: 2), and carrying out secondary fermentation by using lactobacillus combined with Lactobacillus paracasei E10, L. paracasei JN-1 and L. paracasei JN-8 (in a volume ratio of 3: 3: 2). The traditional Chinese medicine composition realizes double synergy of efficient conversion of traditional Chinese medicine active ingredients and intestinal-hepatic axis regulation and control, and is suitable for prevention and adjuvant therapy of alcoholic liver injury and non-alcoholic fatty liver disease.

The invention belongs to the technical field of medical information processing, and particularly discloses a regression model establishment method and system for detecting related indexes of myocardial cells of Wuzhishan pigs by using blood biochemical indexes, and the method comprises the following steps: collecting blood and heart tissue samples of the Wuzhishan pigs at different month ages, detecting the blood biochemical indexes including liver function, blood fat and blood sugar indexes, and establishing a regression model for detecting the related indexes of myocardial cells of the Wuzhishan pigs. Related indexes of myocardial cells; analyzing the index expression quantity difference, and screening significant difference indexes; then calculating the correlation between the remarkably different blood biochemical indexes and myocardial cell related indexes, and determining high-correlation blood biochemical indexes; and finally, constructing a first version of multiple regression model by respectively taking the myocardial enzyme index and the myocardial cell related index as dependent variables and the high-correlation blood biochemical index as an independent variable, removing outliers and updating the sample set on the basis of the first version of multiple regression model, and constructing a second version of multiple regression model by utilizing the new sample set, and on the basis of the second version of multiple regression model, constructing a third version of multiple regression model by adopting a stepwise regression method. According to the method, related indexes of myocardial cells can be accurately deduced through blood biochemical indexes, and support is provided for Wuzhishan pig heart disease research and model animal research and development.

The invention provides a pharmaceutical composition for treating liver injury and hepatic fibrosis, and relates to the technical field of biological medicines. The pharmaceutical composition is prepared from a peucedanum decursum extract, a penthorum chinense pursh extract, a spanishneedles herb extract and a nux prinsepiae extract. The pharmaceutical composition shows an excellent protective effect on a carbon tetrachloride induced hepatocyte injury model. The pharmaceutical composition disclosed by the invention has obvious treatment and protection effects on carbon tetrachloride induced rat hepatic fibrosis, and the anti-hepatic fibrosis effect is realized by improving four indexes of liver function and hepatic fibrosis, reducing the level of inflammatory factors in the liver and relieving inflammatory reaction in the hepatic fibrosis process. The pharmaceutical composition disclosed by the invention is expected to be further developed and popularized as a medicine for treating liver injury and hepatic fibrosis.

To provide an endoplasmic reticulum stress suppressing composition and a liver function improving composition.SOLUTION: A composition for suppressing endoplasmic reticulum stress and / or a composition for improving hepatic functions, comprising one or more plants selected from the group consisting of Plantago asiatica, Hamilton's spindle tree, panicled hydrangea, Japanese plum yew, Japanese mallotus, and Papaver rhoeas, and / or an extract thereof.SELECTED DRAWING: None

The invention belongs to the technical field of medicines, and particularly relates to application of isodan leaf emodin in preparation of an Icam1 inhibitor, related experiments of establishment of a sepsis liver injury model induced by cecum ligation puncture (CLP) show that by applying the isodan leaf emodin, the Icam1 inhibitor can be used for preparing Icam1. According to the present invention, the level of liver tissue proinflammatory factors TNF-alpha, IL-1beta and IL-6 in the liver injury caused by sepsis is reduced, the level of the anti-inflammatory factor IL-10 is increased, and the HE dyeing of the liver tissue proves that the emodin can alleviate the CLP induced inflammatory cell infiltration in the liver tissue, can protect the structural integrity of the liver tissue, and can provide the anti-inflammatory effect on the liver tissue, such that the liver injury caused by sepsis can be inhibited, and the liver injury caused by sepsis can be inhibited. The data shows that the isodan leaf emodin can relieve sepsis liver injury and reduce liver function indexes. In research, it is found for the first time that the action mechanism of the isodan-leaf emodin in relieving the sepsis liver injury is that liver function indexes and inflammatory response are relieved by inhibiting expression of a transmembrane protein intercellular adhesion molecule-1 (Icam1), and it is indicated that the isodan-leaf emodin has a good application prospect in treating sepsis-related tissue injury.

Methods are provided for effectively distinguishing the abilities of a human liver and an extracorporeal liver in an extracorporeal liver perfusion system to extract cholate and, thus, measure relative liver function.

The application discloses application of pyrroloquinoline quinone (PQQ) or a derivative thereof in preparation of a product for relieving or preventing blue-green algae toxin poisoning of yellow catfish, and belongs to the technical field of aquatic animal feed. The PQQ or the derivative thereof can be used as an aquatic feed additive or a medicine, and is added in an amount of 3-6 mg / kg of feed to feed yellow catfish, so as to effectively relieve pathological damage of the liver of the yellow catfish caused by blue-green algae toxin through various ways such as improving key enzyme activity of liver function, inhibiting liver oxidative stress, relieving inflammatory reaction and reducing structural damage of tissues. The PQQ is a new food raw material approved in China in 2022, has advantages of high safety, good water solubility, moderate cost, similar dosage to that of feed vitamins and the like, and provides a safe, economical and convenient new nutritional intervention strategy for blue-green algae toxin poisoning of the yellow catfish, and has a wide industrial application prospect.

The invention relates to the field of biological medicines, and discloses an application of an anti-thymocyte immune globulin preparation in liver transplantation immune induction, which comprises a use method and a dosage of anti-thymocyte immune globulin as an immune inducer in a liver transplantation recipient. Clinical cases prove that liver transplantation recipients use the anti-thymocyte immune globulin as immunosuppressive induction, so that the liver function and lymphocyte level can be quickly recovered to normal ranges, no obvious influence is caused on renal function, the occurrence rate of acute rejection reaction is reduced, the cytomegalovirus infection rate is not increased, and the anti-thymocyte immune globulin can be applied to liver transplantation recipients. Clinical application of the anti-thymocyte immune globulin in immune induction treatment of liver transplantation recipients is expanded, and the anti-thymocyte immune globulin has a great application prospect.

According to the application of the E3 ligase UFL1 modified by the Especially in clearing the SHBs / HBsAg, the SHBs / HBsAg can be cleared by inhibiting the expression of the E3 ligase UFL1 modified by the Especially, so that the effect of treating HBV infection or HBV related diseases is achieved. The strategy of the invention is to directly target and remove the existing SHBs / HBsAg protein, and the action is more direct and rapid. According to the present invention, the inherent protein mass control system (proteasome pathway) of cells is utilized, such that the high biocompatibility and the low off-target toxicity can be provided; and the combination of the strategy and the existing antiviral drugs is expected to further significantly improve the functional cure rate of hepatitis B.

The invention provides a composition and a medicine for preventing and treating acute liver injury and protecting liver. The composition comprises sweet orange flavone and dauricine. According to the traditional Chinese medicine composition disclosed by the invention, through a large number of researches, the sweet orange flavone and the dauricine can be synergistically interacted when being used for preventing and treating the acute liver injury; the sweet orange flavone and dauricine combined treatment group can more effectively relieve liver dysfunction, tissue injury and inflammatory state of acute liver injury model mice. Therefore, the combination of the sweet orange flavone and the dauricine can more effectively prevent and treat the acute liver injury and related diseases of the acute liver injury, and has the effect of protecting the liver.

This invention discloses a method for preparing a co-loaded dual-gene targeted delivery system and its application, involving the construction and preparation of a dual-gene (pHNF4α, pFOXA3) delivery system. This delivery system can target myofibroblasts (MFs) and activated hepatic stellate cells (aHSCs) and can be used for gene therapy of liver fibrosis. This invention synthesizes the targeting carrier material PEI. 25K -PEG 2K -pPB, through electrostatic adsorption, combines with pHNF4α and pFOXA3 to form a co-loaded dual-gene targeted delivery system, F4α / A3@PP-pPB. This delivery system, through the targeting group pPB, binds to MFs (metacellular matrix cells) that lead to excessive accumulation of extracellular matrix in fibrotic livers and to PDGFR (polydimethylformamide) highly expressed on the surface of aHSCs. On the one hand, it inhibits the activation of aHSCs; on the other hand, it transdifferentiates MFs into hepatocyte-like cells (iHep). These two modes, while combating liver fibrosis, can also achieve a certain degree of liver function reconstruction through transdifferentiated iHep cells, providing new ideas and methods for the effective treatment of liver fibrosis.

The invention belongs to the technical field of medicine research, and particularly relates to a gentiana macrophylla extract as well as a preparation method and application thereof. The preparation method of the gentiana macrophylla extract comprises the following steps: by taking gentiana macrophylla as a raw material, adding an ethanol solution with the mass fraction of 70-80%, carrying out heating reflux extraction, collecting an extracting solution, and concentrating to obtain a crude gentiana macrophylla extract; taking an aqueous solution of the gentiana macrophylla crude extract, extracting by taking petroleum ether as an extracting agent, reserving water layer liquid, and drying to obtain a water layer sample; the water layer sample is eluted through macroporous adsorption resin, pure water and an ethanol solution with the mass fraction being 35%-40% are sequentially used as eluents, ethanol eluent is collected and dried, and the water layer sample is obtained. Tests prove that the gentiana macrophylla extract can improve the MASH damp-heat accumulation symptom and liver functions, inhibit the increase of liver proinflammatory cytokines, and relieve MASH hepatic lobule cell fat accumulation, foam and balloon-like degeneration, cell nucleus atrophy and inflammatory lesions.

The application belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to a fermented Lactobacillus muci genus with a function of delaying aging and application thereof. The bacterium was preserved in the Guangdong Microbial Culture Collection Center on August 27, 2025, and the preservation number is GDMCC No: 66877. Experimental results show that the bacterium has excellent antioxidant performance, can relieve oxidative damage, delay aging, inhibit the expression of aging-related genes, and has the ability to improve the memory reproduction ability decline caused by aging, improve the body's anti-inflammatory ability, improve the intestinal flora imbalance induced by aging, and can regulate the level of fat factors, improve energy metabolism, and has the potential of anti-fat deposition and protection of liver function. Therefore, the bacterium can be used to develop products with multiple beneficial functions such as delaying aging, helping to antioxidant, auxiliary improving memory, helping to regulate intestinal flora, and has the advantages of high safety, strong gastrointestinal tolerance, good colonization ability, and has good application value.

The invention discloses application of Psammatlysene D and a derivative thereof in preparation of a medicine for resisting chronic liver diseases, and belongs to the technical field of medicines. The technical scheme of the invention comprises the application of the Psammaglyene D in preparation of a product for resisting chronic liver diseases. The Psammatlyene D can inhibit the growth of LX2 cells, reduce liver function indexes ALT and AST, and relieve the degree of hepatic fibrosis in a mouse body; the growth of liver cancer cells can be inhibited in vivo and in vitro, and a synergistic effect can be generated with sorafenib; meanwhile, the anti-proliferation ability is also shown in sorafenib drug-resistant liver cancer. The derivative B12 of the Psammatlysene D has a stronger in-vitro anti-hepatic fibrosis effect, and the C11 has a very weak inhibition capability on hERG (human endothelial growth factor) and has no potential cardiotoxicity. The results show that the Psammaglyene D has relatively strong capabilities of resisting hepatic fibrosis, inhibiting liver cancer development and relieving sorafenib drug-resistant liver cancer, and the Psammaglyene D and C11 can be used as potential lead compounds for the development of anti-hepatic fibrosis and anti-liver cancer drugs, and are finally applied to the treatment of chronic liver diseases.

The invention belongs to the technical field of biological medicines, and particularly discloses application of a CD44 function inhibitor in preparation of a medicine for preventing or relieving radiation liver injury (RILD). Radioactive liver injury is often caused by hepatocellular carcinoma radiotherapy, and specific targeting drugs are lacked clinically. It is revealed for the first time that whether CD44 molecules on the surface of Kuhu cells are highly expressed after radiation, and the CD44 molecules are key hubs for driving RILD; the invention also provides a CD44 function inhibitor which is a specific targeting drug aiming at RILD, and the action mechanism of the CD44 function inhibitor is to effectively block polarization of radiation-induced Kuptake cells to pro-inflammatory phenotype by inhibiting the CD44 function, so that local inflammatory response, oxidative stress and hepatocyte injury of the liver are relieved. Experiments prove that the CD44 function inhibitor can relieve liver inflammation, improve liver function indexes and reduce liver cell death and tissue pathological damage, and a brand-new and targeted scheme for preventing and treating RILD is provided.

A lipid-containing composition, by weight, includes phospholipids, and one or more of vegetable oil, medium-chain triglycerides, antioxidants, and sodium oleate. It has been verified that the various compositions provided by this invention competitively capture protein-bound toxoids in the blood, thereby achieving the purpose of clearing protein-bound toxoids from the blood, especially for patients with liver failure, and also alleviating oxidative stress in patients during dialysis treatment.

This invention belongs to the technical field of natural product active ingredients, specifically relating to a glycopeptide LBGP-I-b derived from wolfberry and its uses. The glycopeptide LBGP-I-b has an average molecular weight of 700–1000 Da, a polypeptide content of 70%–80%, and a polysaccharide content of 10%–20%. The sugar chains are composed of glucose residues, and the sugar chains are linked to the peptide chains via O-glycopeptide bonds. The glycopeptide has functions such as regulating lipid metabolism, lowering blood lipid levels, and improving liver function. The glycopeptide of this invention has a clear source and stable properties, and has good application prospects in the prevention and treatment of metabolic diseases such as metabolic-related fatty liver disease.

The invention discloses a novel benzothiazole compound as well as a preparation method and application thereof. According to the novel benzothiazole compound, through targeted activation of an RIG-I / OAS innate immune pathway, expression of key proteins and genes such as OAS1 and RIG-I can be rapidly up-regulated, secretion of type I interferon and proinflammatory factors is induced, and instant immune enhancement is achieved; more importantly, by performing long-term functional reprogramming on innate immune cells (such as mononuclear cells and dendritic cells), persistent'innate immune memory '(namely immune domestication) can be induced. The dual-action mechanism can significantly enhance the activation of antigen presenting cells and promote the generation and long-term maintenance of memory B cells and effector memory T cells, has no significant toxicity to liver functions, can be used as an immunologic adjuvant and an immunodomestication molecule of an RSV vaccine, can synergistically improve the vaccine-induced RSV specific antibody titer and neutralizing antibody level, and can be used for preparing an immunologic adjuvant for the RSV vaccine. Long-acting immune protection is provided, and a brand new solution is provided for research and development of RSV vaccines.

The application provides an optimized lactoferricin peptide, a preparation method thereof and application thereof in preparation of anti-inflammatory and anti-oxidative damage preparations, and belongs to the technical field of biological medicines.The application obtains high-biological-activity lactoferricin peptide by optimizing amino acid sites of lactoferricin B; compared with the original lactoferricin B, the optimized lactoferricin peptide has better anti-inflammatory and anti-oxidative effects, can effectively reduce alcohol-induced oxidative damage, fatty degeneration and apoptosis of liver cells, and promote recovery of liver function.The lactoferricin peptide provided by the application can reduce the elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels by about 25% and 20%, respectively.The application provides an application scheme in development of a new generation of polypeptide drugs for treating alcoholic liver disease, hepatitis, acute lung injury and various inflammation oxidative stress related diseases.

The invention provides a composition for improving the thrombolysis capacity of a human body, a preparation method and application thereof.The composition is prepared from, by weight, 5-30 parts of earthworm protein, 30-120 parts of hippophae rhamnoides total flavone extract, 50-150 parts of silymarin extract, 20-80 parts of maltodextrin and 15-60 parts of pregelatinized starch, the earthworm protein activates a fibrinolytic system to promote t-PA to release and dissolve thrombus, and the hippophae rhamnoides total flavone extract activates the fibrinolytic system to promote t-PA to release and dissolve thrombus; the hippophae rhamnoides total flavonoids regulate the ratio of PGI2 / TXA2 to inhibit platelet aggregation and reduce blood fat, the silymarin protects the liver function to enhance LDL-C metabolism clearing, the hippophae rhamnoides total flavonoids, the silymarin and the hippophae rhamnoides total flavonoids cooperate to form a thrombolysis-antithrombosis-metabolism regulation three-dimensional intervention system, a whole-course low-temperature mixing direct tabletting process is adopted

Provided herein is a method of treating liver dysfunction in a patient, comprising administering to the patient a composition that reduces stress in the endoplasmic reticulum in an amount effective to treat the dysfunction in the patient.

The invention discloses a traditional Chinese medicine composition for treating gallstone and a preparation method thereof, and relates to the technical field of traditional Chinese medicine compositions, and the traditional Chinese medicine composition for treating gallstone is characterized by comprising the following components: lysimachia christinae hance, endothelium corneum gigeriae galli, lygodium japonicum, radix curcumae, corn stigma and szechwan chinaberry fruit. Clinical and experiments prove that the traditional Chinese medicine composition can effectively eliminate clinical symptoms of gallstone, and can correct liver function and dyslipidemia, relieve the inflammation level, regulate abnormal metabolism of cholesterol-bile acid, remarkably promote dissolution and discharge of gallstone and inhibit recurrence of gallstone. The traditional Chinese medicine composition not only can effectively prevent and treat gallstone and remarkably relieve clinical symptoms of patients, but also can reduce the treatment cost and avoid pain caused by operations, and has a wide application prospect.

The application relates to the biomedical application field of inorganic materials, and particularly relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy. The application relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy, wherein the medicine comprises lanthanum carbonate and pharmaceutically acceptable adjuvants, and the lanthanum carbonate comprises any one or more of lanthanum carbonate hydrate and basic lanthanum carbonate. The application is based on the fact that glutamine enzyme can reduce blood ammonia, and the hepatic encephalopathy is reversed by reducing blood ammonia and systemic inflammation, the liver function is recovered by regulating inflammation, thereby helping to cure the hepatic encephalopathy, and good treatment effect is shown, so that a new candidate medicine for clinically treating the hepatic encephalopathy is provided.

The invention provides application of an SLC13A3 gene serving as a target spot in preparation of a medicine for treating metabolism-related fatty liver diseases. By constructing an MASLD cell model and an MASLD mouse model with the lesion degree from light to heavy, the expression of the SLC13A3 in the liver tissue and cell model of the metabolism-related fatty liver disease mouse is up-regulated, and the up-regulation multiple is gradually increased along with the increase of the severity of the disease. Animal experiments show that the liver specific knock-down SLC13A3 can significantly relieve weight and liver weight increase, liver fatty degeneration, liver lipid accumulation and liver function impairment accompanied by MASLD, and reduce the expression of adipogenesis genes. The invention provides a new target and a new thought for the development of drugs for treating metabolism-related fatty liver diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to application of PF-06260933 in preparation of a medicine for treating biliary atresia. The invention provides an application of an HGK inhibitor PF-06260933 in preparation of a medicine for treating biliary atresia. A BA organ and biliary duct ligation (BDL) induced mouse model is constructed, PF-06260933 is adopted to inhibit pro-inflammatory and pro-fibrosis related signal channels of biliary duct epithelial cells, and the improvement effect of PF-06260933 on biliary duct atresia pathological phenotypes is observed. Results show that the PF-06260933 treatment not only can significantly improve inflammatory fibrosis phenotypes of BA organs, but also can significantly improve mouse liver functions, relieve liver inflammation and fibrosis, and effectively reverse pathogenic activation phenotypes of bile duct epithelial cells. Compared with the traditional niberous surgery or non-specific immunosuppression therapy, the method has the advantages of remarkable progress and huge clinical application potential.

A fish liver decellularized extracellular matrix based microfluidic 3D printing hydrogel for liver regeneration, and a preparation method thereof are provided. A fish liver decellularized extracellular matrix (dECM) is combined with gelatin methacryloyl (GelMA), and loaded with hepatic spheroids derived from induced pluripotent stem cells (iPSC-hep) for liver regeneration. The fish liver decellularized extracellular matrix based microfluidic 3D printing hydrogel of the present disclosure has excellent biocompatibility and retains intact endogenous growth factors, maintains the biological activity of cells, ensures effective cell encapsulation, and is conducive to robust functional expression of iPSC-hep. After being transplanted in vivo, the hydrogel significantly improves the survival rate and liver function of mice with acute liver failure, and promotes liver regeneration and repair.